YellowGrade
Holy Grail Of Precision Medicine - Co-Development Of Therapeutics And Companion Diagnostics - Hasn’t Yet Achieved Its Potential

Dec. 6, 2022, 8:12 a.m.

(Forbes) Developing a novel biomarker test in parallel with a therapeutic - with the expectation that the biomarker test is going to be included in the FDA-approved label - is accompanied by a set of significant scientific and commercialization challenges.

Login to grade this article.